Abzu® announced that the United States Patent and Trademark Office (USPTO) has issued Abzu Aps a patent number US 11,537,686 titled “Method of Deriving a Correlation” that protects the technology behind the pioneering QLattice® algorithm.
“People who invent and build methods for AI should stop chasing ever more complicated and predictive methods and see if we could instead put the vast potential of AI at the service of science. At Abzu, we have built an AI – the QLattice – that is actually intelligent in the scientific sense of the word,” says Casper Wilstrup, CEO and one of seven co-founders of Abzu.
This inability to understand a system’s internal logic has stymied scientists and researchers in life science industries. Such scientists, as well as their theories, rely on understanding the “why”: E.g., “Why does this disease occur?” or “Why does this drug treat this disease?”
“This is a significant achievement for Abzu,” says Victor Galindo, Software Engineer and one of seven co-founders of Abzu. “The patent granted by USPTO proves that we are on the right track to getting a novel technology into the world.”
Victor, Casper, and all the Abzoids believe scientists and AI researchers can work together to put theory back into the heart of science – where it belongs.
The U.S. patent will expire in 2040.
Abzu empowers scientists to bring drugs to market faster by accelerating their exploration and understanding.
From disease understanding to drug discovery, Abzu has introduced new methods and technology to drive drug discoveries and reduce R&D costs for biotech and pharmaceutical companies.
Founded in January 2018, Abzu is a deep tech startup with offices in Copenhagen, Denmark and Barcelona, Spain.